🚀 #GateNewbieVillageEpisode4 ✖️ @比特一哥 
📈 Follow the trend, pick your points, wait for the signal 
💬 Share your trading journey | Discuss strategies | Grow with the Gate Family 
⏰ Event Date: Oct 25 04:00 – Nov 2 16:00 UTC 
How to Join: 
1️⃣ Follow Gate_Square + @比特一哥 
2️⃣ Post on Gate Square with the hashtag #GateNewbieVillageEpisode4  
3️⃣ Share your trading growth, insights, or experience 
— The more genuine and insightful your post, the higher your chance to win! 
🎁 Rewards 
3 lucky participants → Gate X RedBull Cap + $20 Position Voucher 
If delivery is unavailable, replaced with a $30 Position V
Novo Nordisk plans to acquire Metsera for $9 billion, challenging Pfizer's established deal.
Jin10 data reported on October 31 that Danish pharmaceutical company Novo Nordisk (NVO.N) launched a proactive acquisition of obesity drug developer Metsera on Thursday, with an offer of up to $9 billion, aiming to surpass the $7.3 billion deal reached by Pfizer (PFE.N) last month, which may trigger legal actions against the biotech company. The company proposed to acquire Metsera for $56.50 per share in cash, with an additional payment of $21.25 per share upon achieving specific milestones. Metsera stated in a separate announcement that Novo Nordisk's new offer is superior to the Pfizer proposal. According to the protocol, Pfizer currently has four days to modify the original proposal, and if Metsera ultimately determines the new offer is better, it has the right to terminate the agreement with Pfizer. Following the announcement, Metsera's stock price surged over 20%, with a cumulative rise of 78% over the past three months, while Novo Nordisk's stock price in Copenhagen fell nearly 4%.